February 26, 2025, the “Thematic Seminar on Biotechnology Innovation and Translation Project”, organized by The Hong Kong Bio-Med Innotech Association (HKBMIA), was successfully held. The seminar aims to share a series of achievements of the project and conduct presentations and discussions on the industry's hotspots, to explore the innovations of the biopharmaceutical industry and the direction of its future development. Dr. LI Xiaoyi, Founder of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", HKEx:00950), was invited to participate in the event.

Hong Kong, December 20, 2024 - The “STEM Experience Program for Secondary Students——Kanya Lee Scholarship Recognition Ceremony 2024” was successfully held in Hong Kong Disneyland Hotel.

Recently, the list of the 2024 “New Force Enterprises” of Hefei High-tech Zone was announced. Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke- Hefei”), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group”, stock code: 00950), was successfully recognized as “New Force Enterprise” for its outstanding performance in technological innovation, industrial influence, and new market development strategy.

Recently, the Hefei Science and Technology Bureau of Anhui Province announced the proposed list of “New Technologies, New Products, and New Models in Hefei for 2024.” After rounds of selection, the Treprostinil Injection, a product of Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke Hefei”), which is a wholly-owned subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group”, stock code: 00950), was successfully recognized as a “New Product” in the biopharmaceutical industry and was included in the “New Product Promotion and Application Directory of Hefei”.

The 12th China Cervical Cancer Prevention and Control Academic Annual Conference, hosted by the China Cervical Cancer Prevention and Control Engineering Committee, was successfully held in Chongqing from 17-20 October 2024. The conference aimed to standardize diagnosis and treatment pathways and achieve precise diagnosis and management for cervical cancer. Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke Hefei”), a subsidiary of Lee's Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group”, HKEx:00950), participated in the event and once again won the “Social Responsibility Award.”

The Hong Kong International Biotechnology Forum and Exhibition (BIOHK2024), organized by the Hong Kong Biotechnology Organization, was successfully held at the Hong Kong Convention and Exhibition Centre (HKCEC) on 11-14 September 2024. It is one of Asia’s largest international biotechnology conventions which aims to facilitate the exchange of ideas among international industry players and foster biotechnology innovation in Hong Kong. Lee's Pharmaceutical (HK) Limited ("Lee's Pharm" or the "Group", HKEx:00950), as a Silver Sponsor, continued to support the event.

The 2024 China Medical and Health Industry Symbiosis Conference, organized by Menet, a healthcare information platform, was grandly held in Huzhou from 25 to 28 June, 2024. A number of lists were released during the conference, including the “China Pharmaceutical Industry Top 100 Series List” and the “Most Valuable Product in Partnership for Drug Store Chain”.

May 30, 2024, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) grandly held the launch ceremony at its Guangzhou Nansha site for its new product Adapalene and Clindamycin Hydrochloride Gel. The Group’s Managing Director, Ms. Wanee Leelalertsuphakun, and staff members of different departments were present at the event to jointly witness the start of a new chapter in acne treatment marked by the product.

Recently, the "Symposium on the Progress of Nitric Oxide Inhalation Therapy in Newborns" organized by the Shanghai Caritas Foundation took place at the Guangzhou Southern Airlines Pearl Airport Hotel. During the conference, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) held a launch event for its new rare disease products, Nitric Oxide for Inhalation (INOmax®) and INOmax DSIR Plus Delivery System.

May 15, 2024, the high-profile 88th PharmChina was grandly opened at the Shanghai National Exhibition and Convention Center. As a significant event in the industry, the exhibition attracted 150,000 visitors and brought together nearly 4,000 pharmaceutical companies to showcase their latest products and technological achievements. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) participated in the event.

Recently, the Guangdong High-tech Association granted the certificates of “Guangdong Prominent High-tech Products” for 2023. The Azilsartan Tablets, an in-house developed product of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), won the award by virtue of its outstanding innovation capacity, advanced technology, reliable quality and good market prospect.

Recently, the Hefei Municipal Department of Economy and Information Technology announced the list of “Safe Enterprises” for the year 2023. After several rounds of selection, Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke-Hefei”), a subsidiary of Lee's Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group”, HKEx:00950), has been honored with this title.